NKGen Biotech (NKGN) News Today → Charles Payne Demystifies Options (From Unstoppable Prosperity) (Ad) Free NKGN Stock Alerts $1.13 -0.01 (-0.88%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 8:05 AM | globenewswire.comNKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & ExhibitionApril 29, 2024 | marketwatch.comNKGen Biotech Shares Rise 15% After FDA Clears Application for Parkinson's Disease TherapyApril 29, 2024 | markets.businessinsider.comNKGen Biotech: FDA Clears IND Application For SNK01 NK Cell Therapy - Quick FactsApril 29, 2024 | finance.yahoo.comNKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s DiseaseApril 29, 2024 | globenewswire.comNKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson's DiseaseApril 25, 2024 | finance.yahoo.comNKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development SummitApril 25, 2024 | globenewswire.comNKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development SummitApril 24, 2024 | globenewswire.comNKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 22, 2024 | finance.yahoo.comReplicate Bioscience Announces Oral Presentations at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual MeetingApril 22, 2024 | finance.yahoo.comWhat's Going On With Nano-Cap NKGen Biotech Stock On Monday?April 18, 2024 | finance.yahoo.comNKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development SummitApril 18, 2024 | globenewswire.comNKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development SummitApril 17, 2024 | investorplace.comNKGN Stock Earnings: NKGen Biotech Reported Results for Q4 2023April 11, 2024 | globenewswire.comNKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical ProgramsMarch 25, 2024 | globenewswire.comNKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's Disease at the Tau2024 Global ConferenceMarch 22, 2024 | investing.comNKGen Biotech appoints new chairperson amid leadership shuffleMarch 6, 2024 | investorplace.comWhy Is NKGen Biotech (NKGN) Stock Up 62% Today?March 4, 2024 | finance.yahoo.comNKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global ConferenceMarch 4, 2024 | globenewswire.comNKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer's Disease at the Tau2024 Global ConferenceFebruary 9, 2024 | msn.comAlana McNulty Exits NKGen Biotech’s Board and CommitteesFebruary 7, 2024 | finance.yahoo.comPassage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy CompaniesJanuary 3, 2024 | investing.comNKGen Biotech Inc (NKGN)December 29, 2023 | finance.yahoo.comNKGen Biotech Advances Alzheimer's Treatment with SNK01: First Patient Dosed in Phase 1/2a TrialDecember 28, 2023 | finance.yahoo.comNKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer’s DiseaseDecember 27, 2023 | marketwatch.comNKGen Biotech Gets Clearance to Begin Alzheimer's Disease Treatment Trials in CanadaDecember 27, 2023 | markets.businessinsider.comNKGen Biotech Receives Clearance For SNK01 NK Cell Therapy Clinical Trial From Health CanadaDecember 27, 2023 | finance.yahoo.comNKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s DiseaseNovember 30, 2023 | seekingalpha.comNKGN NKGen Biotech, Inc.November 15, 2023 | seekingalpha.comNKGen Biotech GAAP EPS of -$2.48November 14, 2023 | finance.yahoo.comNKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business HighlightsNovember 7, 2023 | morningstar.comNKGen Biotech Inc NKGNNovember 7, 2023 | finance.yahoo.comNKGen Announces Poster Presentation at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023November 7, 2023 | finance.yahoo.comNKGen Biotech Presents Interim Phase I Trial Data at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023November 7, 2023 | finance.yahoo.comNKGen Biotech Announces Poster Presentation at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceNovember 7, 2023 | finance.yahoo.comNKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer’s DiseaseNovember 7, 2023 | finance.yahoo.comNKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.November 7, 2023 | finance.yahoo.comNKGen Biotech Presented Phase I Clinical Trial Data at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceOctober 27, 2023 | investorplace.comWhy Is NKGen Biotech (NKGN) Stock Up 18% Today? Get NKGen Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Charles Payne Demystifies Options (Ad)When it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. NKGN Media Mentions By Week NKGN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NKGN News Sentiment▼0.000.55▲Average Medical News Sentiment NKGN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NKGN Articles This Week▼11▲NKGN Articles Average Week Get NKGen Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Pluri News Surrozen News MiNK Therapeutics News Protara Therapeutics News Brainstorm Cell Therapeutics News Achilles Therapeutics News AIM ImmunoTech News ZIVO Bioscience News Evaxion Biotech A/S News SAB Biotherapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:NKGN) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersCharles Payne Demystifies OptionsUnstoppable ProsperityGold Set to EXPLODE!Gold Safe ExchangeBiden FINISHED On June 13th?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingHow Biden has already won 2024Porter & CompanyWhy Is Gold On a MASSIVE rally? Huge AlertsProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.